Navigation Links
The Deal Names Abbott Top Dealmaker for Second Consecutive Year

ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective strategic use of acquisitions and divestitures since January 2006.

Over the past decade, Abbott has reshaped its business portfolio with a focus on high-growth, innovation-driven businesses with market-leading potential. In the past 12 months, Abbott has initiated more than $10 billion in strategic transactions that have diversified product and pipeline portfolios, added new technology and accelerated expansion into key global emerging markets.

"Abbott has a strong and successful track record of acquiring small- to mid-size companies and technologies with the potential for long-term growth and market leadership," said Miles D. White, chairman and chief executive officer, Abbott. "Over the past 12 months, Abbott has announced seven strategic acquisitions that will enhance the diversity of our portfolio and expand our global reach to deliver industry-leading returns to our shareholders."

In 2009, Abbott has:

  • Announced the purchase of a novel compound in development to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced its intent to acquire Solvay Pharmaceuticals, complementing its existing portfolio and expanding infrastructure in key global emerging markets.
  • Acquired Evalve, entering the emerging field of non-surgical treatment for heart valve repair.
  • Purchased Visiogen, gaining a next-generation technology to treat cataracts.
  • Announced plans to acquire the nutrition business of Wockhardt, Ltd., positioning Abbott to be a leader in India.
  • Purchased Advanced Medical Optics, gaining immediate leadership in the multi-billion dollar eye care market.
  • Enhanced its leading-edge technology in diagnostic testing and surveillance with the addition of award-winning IBIS Biosciences.

Other key acquisitions within the timeframe for award consideration:

  • Purchased Kos Pharmaceuticals, immediately enhancing Abbott's existing franchise and portfolio strength in the $20 billion lipid management market with Niaspan® (niacin extended-release tablets), a best-in-class therapy for raising HDL "good" cholesterol.
  • Acquired Guidant's vascular business, providing Abbott with the current market-leading drug-eluting stent, XIENCE V(TM), and the world's first bioabsorbable drug-eluting stent to enter clinical trials.

The Deal's readers rated Abbott best on all four of its award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team. Companies considered for the survey have a market capitalization of $5 billion or more as of June 30, 2009, and closed the highest number and dollar value of acquisitions and divestitures in the past three and a half years.

About The Deal LLC

The Deal LLC, (, is a diversified media company that is the authoritative voice of the deal economy. The Deal LLC serves the global deal community - corporate and financial dealmakers, advisers and institutional investors - by providing business and financial news and information that offers fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate growth in a continually changing global market. The Deal LLC offers a comprehensive line of print and electronic products - The Deal, The Daily Deal and - and live annual events including Private Capital Symposium, Distressed Investing Forum, Corporate Dealmaker Forum and M&A Outlook. The Deal LLC, a privately held company, is owned by private investment funds, including U.S. Equity Partners LP, sponsored by Wasserstein & Co. LP.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
2. AMD LASERS Names Dr. James Jesse as Medical Director
3. Arcadia Resources Names Stephen Goldsmith to Board of Directors
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. Codexis Names Fernando Valle Research Fellow
6. Veridiam Names Robert Mazzacavallo New CFO
7. Hospira Names Daphne E. Jones Chief Information Officer
8. Premier Research Names Bernard Sweeney as Executive Director, Medical Devices
9. American Hospital Association (AHA) Names OnBase RACTrac Compatible
10. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
11. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Smiles by Stevens is pleased to announce ... wrinkling. While many patients are aware of the benefits of Botox® in the treatment ... those suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ ...
(Date:11/25/2015)... ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Smart and Beddit Classic sleep tracking systems. The new app features a more intuitive ... see and understand how well you slept. The SleepScore is created by a proprietary ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study ... (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product and ... care units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):